002166 莱茵生物
已收盘 11-22 15:00:00
资讯
新帖
简况
莱茵生物(002166)301.86万股限售股将于11月21日解禁,占总股本0.41%
证券之星 · 11-21
莱茵生物(002166)301.86万股限售股将于11月21日解禁,占总股本0.41%
莱茵生物(002166)股东秦本军质押400万股,占总股本0.54%
证券之星 · 11-20
莱茵生物(002166)股东秦本军质押400万股,占总股本0.54%
华鑫证券:给予莱茵生物买入评级
证券之星 · 11-03
华鑫证券:给予莱茵生物买入评级
莱茵生物:10月31日接受机构调研,华鑫证券、上海杭贵投资等多家机构参与
证券之星 · 11-01
莱茵生物:10月31日接受机构调研,华鑫证券、上海杭贵投资等多家机构参与
莱茵生物(002166)2024年三季报简析:营收净利润同比双双增长,盈利能力上升
证券之星 · 11-01
莱茵生物(002166)2024年三季报简析:营收净利润同比双双增长,盈利能力上升
天风证券:给予莱茵生物买入评级
证券之星 · 10-31
天风证券:给予莱茵生物买入评级
图解莱茵生物三季报:第三季度单季净利润同比增680.75%
证券之星 · 10-31
图解莱茵生物三季报:第三季度单季净利润同比增680.75%
莱茵生物(002166.SZ)发布前三季度业绩,净利润1.02亿元,同比增长148.46%
智通财经 · 10-30
莱茵生物(002166.SZ)发布前三季度业绩,净利润1.02亿元,同比增长148.46%
莱茵生物、劲拓股份两公司实控人操纵股价,投资者索赔征集公告
市场资讯 · 10-22
莱茵生物、劲拓股份两公司实控人操纵股价,投资者索赔征集公告
莱茵生物(002166.SZ)部分董事高管减持期满 共减持584.52万股
智通财经 · 10-09
莱茵生物(002166.SZ)部分董事高管减持期满 共减持584.52万股
莱茵生物最新公告:拟通过债转股方式对全资子公司增资1.95亿元
证券之星 · 10-08
莱茵生物最新公告:拟通过债转股方式对全资子公司增资1.95亿元
莱茵生物(002166)股东秦本军质押150万股,占总股本0.2%
证券之星 · 10-08
莱茵生物(002166)股东秦本军质押150万股,占总股本0.2%
莱茵生物股票索赔条件有变化,实控人涉嫌操纵股价拟受罚,受损股民可索赔
市场资讯 · 10-08
莱茵生物股票索赔条件有变化,实控人涉嫌操纵股价拟受罚,受损股民可索赔
莱茵生物涨8.63%,天风证券一周前给出“买入”评级
证券之星 · 09-30
莱茵生物涨8.63%,天风证券一周前给出“买入”评级
天风证券:给予莱茵生物买入评级
证券之星 · 09-22
天风证券:给予莱茵生物买入评级
莱茵生物最新公告:合成生物车间项目正式投产
证券之星 · 09-20
莱茵生物最新公告:合成生物车间项目正式投产
莱茵生物(002166.SZ):合成生物车间项目正式投产
智通财经网 · 09-20
莱茵生物(002166.SZ):合成生物车间项目正式投产
莱茵生物:预计2024年1-9月归属净利润盈利8180.14万元至1.02亿元
证券之星 · 09-19
莱茵生物:预计2024年1-9月归属净利润盈利8180.14万元至1.02亿元
莱茵生物(002166.SZ)发预增,预计前三季度净利润8180.14万元至1.02亿元,同比增长100%至150%
智通财经 · 09-19
莱茵生物(002166.SZ)发预增,预计前三季度净利润8180.14万元至1.02亿元,同比增长100%至150%
莱茵生物:前三季度净利润同比增长100%-150%
美港电讯 · 09-19
莱茵生物:前三季度净利润同比增长100%-150%
公司概况
公司名称:
桂林莱茵生物科技股份有限公司
所属行业:
医药制造业
上市日期:
2007-09-13
主营业务:
桂林莱茵生物科技股份有限公司主要从事天然健康产品业务,主要产品是罗汉果提取物、甜叶菊提取物、工业大麻提取物、茶叶提取物及其他保健护肤提取物。公司先后获得“植物提取物优质供应商”、“中国质量诚信企业”、“中国农业企业500强”等殊荣,2023年顺利通过“国家级专精特新小巨人企业”、“农业产业化国家重点龙头企业”等荣誉复审,作为植物提取行业绿色转型升级的示范标杆企业更是取得了“国家级绿色工厂”的荣誉称号。
发行价格:
9.89
{"stockData":{"symbol":"002166","market":"SZ","secType":"STK","nameCN":"莱茵生物","latestPrice":7.74,"timestamp":1732259034000,"preClose":8.04,"halted":0,"volume":11711630,"delay":0,"floatShares":517000000,"shares":742000000,"eps":0.1931,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.3,"latestTime":"11-22 15:00:00","open":8,"high":8.04,"low":7.72,"amount":92501900,"amplitude":0.0398,"askPrice":7.75,"askSize":576,"bidPrice":7.74,"bidSize":1963,"shortable":0,"etf":0,"ttmEps":0.1931,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"adjPreClose":8.04,"symbolType":"stock","openAndCloseTimeList":[[1732239000000,1732246200000],[1732251600000,1732258800000]],"highLimit":8.84,"lowLimit":7.24,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":741986825,"pbRate":1.96,"roa":"--","roe":"3.28%","epsLYR":0.11,"committee":0.527759,"marketValue":5743000000,"floatMarketCap":3998000000,"peRate":40.082858,"changeRate":-0.0373,"turnoverRate":0.0227,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2024-11-25。"},"requestUrl":"/m/hq/s/002166/wiki","defaultTab":"wiki","newsList":[{"id":"2485105746","title":"莱茵生物(002166)301.86万股限售股将于11月21日解禁,占总股本0.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485105746","media":"证券之星","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485105746?lang=zh_cn&edition=full","pubTime":"2024-11-21 08:04","pubTimestamp":1732147463,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息整理,莱茵生物于11月21日将有301.86万股限售股份解禁,为公司股权激励限售股份,占公司总股本0.41%。本次解禁后,公司还有2.25亿股限售股份,占总股本30.38%。莱茵生物主营业务:天然健康产品的生产经营业务,持续专注植物功能性成分提取领域。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112100005997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0168","BK0028","BK0174","002166","BK0239","BK0046"],"gpt_icon":0},{"id":"2484178974","title":"莱茵生物(002166)股东秦本军质押400万股,占总股本0.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484178974","media":"证券之星","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484178974?lang=zh_cn&edition=full","pubTime":"2024-11-20 03:22","pubTimestamp":1732044121,"startTime":"0","endTime":"0","summary":"证券之星消息,莱茵生物11月20日公开信息显示,股东秦本军向华夏银行股份有限公司桂林分公司合计质押400.0万股,占总股本0.54%。莱茵生物主营业务:天然健康产品的生产经营业务,持续专注植物功能性成分提取领域。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112000004711.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0174","BK0168","BK0028","BK0239","BK0046","002166"],"gpt_icon":0},{"id":"2480381310","title":"华鑫证券:给予莱茵生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2480381310","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480381310?lang=zh_cn&edition=full","pubTime":"2024-11-03 09:25","pubTimestamp":1730597125,"startTime":"0","endTime":"0","summary":"华鑫证券有限责任公司胡博新,孙山山,张倩近期对莱茵生物进行研究并发布了研究报告《公司事件点评报告:植提业务稳步增长,产能建设按计划落地》,本报告对莱茵生物给出买入评级,当前股价为7.99元。 莱茵生物 事件 2024年10月30日,莱茵生物发布2024年三季度报告。最新盈利预测明细如下:该股最近90天内共有3家机构给出评级,买入评级3家。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110300000259.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002166","161027"],"gpt_icon":0},{"id":"2480014304","title":"莱茵生物:10月31日接受机构调研,华鑫证券、上海杭贵投资等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2480014304","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480014304?lang=zh_cn&edition=full","pubTime":"2024-11-01 09:47","pubTimestamp":1730425627,"startTime":"0","endTime":"0","summary":"证券之星消息,2024年10月31日莱茵生物发布公告称公司于2024年10月31日接受机构调研,华鑫证券孙山山 张倩 张卉琦、上海杭贵投资饶欣莹、深圳市果盈资产林晓珊、北京泾谷私募基金高艺、宁波三登投资倪娜、北京大家投资张翔、北京橡果资产魏鑫、上海丰仓股权投资基金路永光、浙商证券杜宛泽、天风国际冯梦媛、财通证券王子昂、野村东方国际证券周悦琅、东北证券陈科诺、鸿运私募基金高波、深圳中天汇富基金慕陶、天治基金王策源参与。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110100012289.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0174","002166","161027","BK0239","BK0046","BK0168"],"gpt_icon":0},{"id":"2480109989","title":"莱茵生物(002166)2024年三季报简析:营收净利润同比双双增长,盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2480109989","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480109989?lang=zh_cn&edition=full","pubTime":"2024-11-01 06:39","pubTimestamp":1730414387,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期莱茵生物发布2024年三季报。截至本报告期末,公司营业总收入11.7亿元,同比上升31.61%,归母净利润1.02亿元,同比上升148.46%。按单季度数据看,第三季度营业总收入4.44亿元,同比上升17.96%,第三季度归母净利润3672.86万元,同比上升680.75%。本报告期莱茵生物盈利能力上升,毛利率同比增幅22.55%,净利率同比增幅51.64%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110100007161.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002166"],"gpt_icon":0},{"id":"2479703222","title":"天风证券:给予莱茵生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2479703222","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479703222?lang=zh_cn&edition=full","pubTime":"2024-10-31 18:16","pubTimestamp":1730369782,"startTime":"0","endTime":"0","summary":"天风证券股份有限公司吴立,杨松近期对莱茵生物进行研究并发布了研究报告《24前三季度植提业务大幅增长,合成生物车间投产夯实技术壁垒》,本报告对莱茵生物给出买入评级,当前股价为8.15元。公司植物提取业务稳健增长,看好合成生物车间核心产品商业化前景,以及对未来工业大麻市场的快速提升有信心,维持“买入”评级。最新盈利预测明细如下:该股最近90天内共有3家机构给出评级,买入评级3家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100037868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002166","601162"],"gpt_icon":0},{"id":"2479790758","title":"图解莱茵生物三季报:第三季度单季净利润同比增680.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479790758","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479790758?lang=zh_cn&edition=full","pubTime":"2024-10-31 01:58","pubTimestamp":1730311119,"startTime":"0","endTime":"0","summary":"证券之星消息,莱茵生物2024年三季报显示,公司主营收入11.7亿元,同比上升31.61%;归母净利润1.02亿元,同比上升148.46%;扣非净利润1.05亿元,同比上升2789.46%;其中2024年第三季度,公司单季度主营收入4.44亿元,同比上升17.96%;单季度归母净利润3672.86万元,同比上升680.75%;单季度扣非净利润3916.58万元,同比上升11411.63%;负债率36.91%,投资收益717.93万元,财务费用2483.46万元,毛利率28.16%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100003050.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002166"],"gpt_icon":0},{"id":"2479011082","title":"莱茵生物(002166.SZ)发布前三季度业绩,净利润1.02亿元,同比增长148.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479011082","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479011082?lang=zh_cn&edition=full","pubTime":"2024-10-30 20:23","pubTimestamp":1730291010,"startTime":"0","endTime":"0","summary":"智通财经APP讯,莱茵生物(002166.SZ)发布2024年三季度报告,前三季度,公司实现营业收入11.7亿元,同比增长31.61%。归属于上市公司股东的净利润1.02亿元,同比增长148.46%。归属于上市公司股东的扣除非经常性损益的净利润1.05亿元,同比增长2789.46%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1204077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002166"],"gpt_icon":0},{"id":"2477811827","title":"莱茵生物、劲拓股份两公司实控人操纵股价,投资者索赔征集公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2477811827","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477811827?lang=zh_cn&edition=full","pubTime":"2024-10-22 11:14","pubTimestamp":1729566840,"startTime":"0","endTime":"0","summary":" 莱茵生物002166,因为这家公司的实际控制人操纵自家股票一事,在证券市场反响很大。 2023年5月11日,莱茵生物发布《关于公司实际控制人收到立案告知书的公告》,因实际控制人秦本军涉嫌操纵证券市场被中国证监会立案。 秦本军为莱茵生物的第一大股东、实际控制人,截止到目前,秦本军持有莱茵生物的比例为36.58%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/gmwq/rightscase/2024-10-22/doc-inctkvpi8065570.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/gmwq/rightscase/2024-10-22/doc-inctkvpi8065570.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK0046","BK0251","BK0130","BK0132","BK0174","BK0239","BK0168","002166","300400","BK0089"],"gpt_icon":0},{"id":"2474024352","title":"莱茵生物(002166.SZ)部分董事高管减持期满 共减持584.52万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2474024352","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474024352?lang=zh_cn&edition=full","pubTime":"2024-10-09 19:01","pubTimestamp":1728471687,"startTime":"0","endTime":"0","summary":"智通财经APP讯,莱茵生物(002166.SZ)发布公告,截至目前,公司董事、常务副总经理谢永富先生,董事、副总经理白昱先生,副总经理、董事会秘书罗华阳先生,财务总监郑辉女士及原董事姚新德先生本次减持计划期限已届满,本次减持共计584.52万股,减持比例0.80%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1191882.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0174","002166","BK0028","BK0239","BK0046","BK0168"],"gpt_icon":0},{"id":"2473420670","title":"莱茵生物最新公告:拟通过债转股方式对全资子公司增资1.95亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2473420670","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473420670?lang=zh_cn&edition=full","pubTime":"2024-10-08 21:30","pubTimestamp":1728394231,"startTime":"0","endTime":"0","summary":"莱茵生物公告,公司拟通过债转股的方式对全资子公司上海碧研生物技术有限公司进行增资,增资金额为1.95亿元,本次增资资金将全部计入资本公积。本次增资不会导致公司合并报表范围发生变化,亦不会对公司的财务状况和经营状况产生重大不利影响。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024100800037868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0174","BK0028","002166","BK0046","BK0168"],"gpt_icon":0},{"id":"2473420604","title":"莱茵生物(002166)股东秦本军质押150万股,占总股本0.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2473420604","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473420604?lang=zh_cn&edition=full","pubTime":"2024-10-08 21:28","pubTimestamp":1728394121,"startTime":"0","endTime":"0","summary":"证券之星消息,莱茵生物10月8日公开信息显示,股东秦本军向国海证券合计质押150.0万股,占总股本0.2%。莱茵生物主营业务:天然健康产品的生产经营业务,持续专注植物功能性成分提取领域。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024100800037822.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","BK0168","002166","BK0239","BK0174"],"gpt_icon":0},{"id":"2473605404","title":"莱茵生物股票索赔条件有变化,实控人涉嫌操纵股价拟受罚,受损股民可索赔","url":"https://stock-news.laohu8.com/highlight/detail?id=2473605404","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473605404?lang=zh_cn&edition=full","pubTime":"2024-10-08 11:40","pubTimestamp":1728358800,"startTime":"0","endTime":"0","summary":" 近日,代理过多件重大影响案件的江苏博爱星律师事务所章祥兵律师特别提示,莱茵生物(维权)股票索赔条件有变化,实控人涉嫌操纵股价拟受罚,受损股民可索赔。 2024年3月13日,桂林莱茵生物科技股份有限公司发布公告称,公司接到实控人秦本军先生告知,获悉其收到证监会的《行政处罚及市场禁入事先告知书》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/gmwq/rightscase/2024-10-08/doc-incrvhaz0912219.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/gmwq/rightscase/2024-10-08/doc-incrvhaz0912219.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0174","002166","BK0028","BK0239","BK0046","BK0168"],"gpt_icon":0},{"id":"2471725218","title":"莱茵生物涨8.63%,天风证券一周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2471725218","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471725218?lang=zh_cn&edition=full","pubTime":"2024-09-30 18:05","pubTimestamp":1727690715,"startTime":"0","endTime":"0","summary":"今日莱茵生物涨8.63%,收盘报8.31元。2024年9月21日,天风证券研究员吴立,杨松发布了对莱茵生物的研报《24前三季度归母净利润预计延续高增长,看好产能释放提升盈利能力》,该研报对莱茵生物给出“买入”评级。公司天然甜味剂业务稳健增长,看好天然甜味剂大订单持续放量,以及对未来工业大麻市场的快速提升有信心,维持“买入”评级。莱茵生物个股概况:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024093000031890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002166","601162"],"gpt_icon":0},{"id":"2469108679","title":"天风证券:给予莱茵生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2469108679","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469108679?lang=zh_cn&edition=full","pubTime":"2024-09-22 09:15","pubTimestamp":1726967715,"startTime":"0","endTime":"0","summary":"天风证券股份有限公司吴立,杨松近期对莱茵生物进行研究并发布了研究报告《24前三季度归母净利润预计延续高增长,看好产能释放提升盈利能力》,本报告对莱茵生物给出买入评级,当前股价为6.94元。公司天然甜味剂业务稳健增长,看好天然甜味剂大订单持续放量,以及对未来工业大麻市场的快速提升有信心,维持“买入”评级。最新盈利预测明细如下:该股最近90天内共有3家机构给出评级,买入评级3家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092200000727.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002166","601162"],"gpt_icon":0},{"id":"2468640126","title":"莱茵生物最新公告:合成生物车间项目正式投产","url":"https://stock-news.laohu8.com/highlight/detail?id=2468640126","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468640126?lang=zh_cn&edition=full","pubTime":"2024-09-20 20:30","pubTimestamp":1726835406,"startTime":"0","endTime":"0","summary":"莱茵生物公告,公司合成生物车间项目于2024年9月20日正式投产运营。该项目总投资约2.1亿元,车间建筑面积约1.22万平方米,配备了12条全自动化的精密发酵产线。项目全面达产后,公司预计每年可生产合成生物相关产品1000吨以上,年产值超过10亿元。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092000037460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002166","BK0046","BK0239","BK0168","BK0028","BK0174"],"gpt_icon":0},{"id":"2468403496","title":"莱茵生物(002166.SZ):合成生物车间项目正式投产","url":"https://stock-news.laohu8.com/highlight/detail?id=2468403496","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468403496?lang=zh_cn&edition=full","pubTime":"2024-09-20 20:30","pubTimestamp":1726835406,"startTime":"0","endTime":"0","summary":"智通财经APP讯,莱茵生物(002166.SZ)发布公告,2023年初公司正式启动合成生物车间的建设和投资,旨在建立业内领先的合成生物技术生产天然健康成分的生产线,以全面提升公司在全球合成生物领域的技术转移和产业化落地承接能力。2024年9月20日,公司合成生物车间项目的建设全面完成安装调试并正式投产运营。该车间全面达产后,公司预计每年可生产合成生物相关产品1000吨以上,年产值超过10亿元。更多港股重磅资讯,下载智通财经app更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1185448.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["002166","BK0028","BK0174","BK0168","BK0046","BK0239"],"gpt_icon":0},{"id":"2468250529","title":"莱茵生物:预计2024年1-9月归属净利润盈利8180.14万元至1.02亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2468250529","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468250529?lang=zh_cn&edition=full","pubTime":"2024-09-19 18:00","pubTimestamp":1726740033,"startTime":"0","endTime":"0","summary":"证券之星消息,莱茵生物发布业绩预告,预计2024年1-9月归属净利润盈利8180.14万元至1.02亿元。莱茵生物2024年中报显示,公司主营收入7.25亿元,同比上升41.65%;归母净利润6489.31万元,同比上升79.28%;扣非净利润6535.93万元,同比上升1548.95%;其中2024年第二季度,公司单季度主营收入3.84亿元,同比上升48.06%;单季度归母净利润3810.3万元,同比上升134.35%;单季度扣非净利润2578.84万元,同比上升683.56%;负债率37.1%,投资收益736.29万元,财务费用1205.23万元,毛利率28.6%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024091900028411.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002166"],"gpt_icon":0},{"id":"2468952630","title":"莱茵生物(002166.SZ)发预增,预计前三季度净利润8180.14万元至1.02亿元,同比增长100%至150%","url":"https://stock-news.laohu8.com/highlight/detail?id=2468952630","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468952630?lang=zh_cn&edition=full","pubTime":"2024-09-19 17:31","pubTimestamp":1726738312,"startTime":"0","endTime":"0","summary":"智通财经APP讯,莱茵生物(002166.SZ)披露2024年前三季度业绩预告,公司预计前三季度归属于上市公司股东的净利润8180.14万元–1.02亿元,同比增长100%-150%;归属于上市公司股东扣除非经常性损益后的净利润8077.14万元–1.01亿元,同比增长2132.80%-2698.11%。报告期内,公司主营业务延续高增长态势,预计实现营业收入较去年同期增长约30%,归属于上市公司股东的净利润将同比增长100%-150%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1184671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002166"],"gpt_icon":0},{"id":"2468230755","title":"莱茵生物:前三季度净利润同比增长100%-150%","url":"https://stock-news.laohu8.com/highlight/detail?id=2468230755","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468230755?lang=zh_cn&edition=full","pubTime":"2024-09-19 17:20","pubTimestamp":1726737636,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0046","002166","BK0174","BK0239","BK0028","BK0168"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2007-09-13","address":"广西壮族自治区桂林市临桂区人民南路19号","stockEarnings":[{"period":"1week","weight":-0.0361},{"period":"1month","weight":-0.0313},{"period":"3month","weight":0.171},{"period":"6month","weight":-0.0019},{"period":"1year","weight":-0.0117},{"period":"ytd","weight":0.0226}],"companyName":"桂林莱茵生物科技股份有限公司","boardCode":"AI0027","perCapita":"9060股","boardName":"医药制造业","registeredCapital":"74198万元","compareEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.0108},{"period":"3month","weight":0.1446},{"period":"6month","weight":0.0577},{"period":"1year","weight":0.0671},{"period":"ytd","weight":0.0982}],"survey":" 桂林莱茵生物科技股份有限公司主要从事天然健康产品业务,主要产品是罗汉果提取物、甜叶菊提取物、工业大麻提取物、茶叶提取物及其他保健护肤提取物。公司先后获得“植物提取物优质供应商”、“中国质量诚信企业”、“中国农业企业500强”等殊荣,2023年顺利通过“国家级专精特新小巨人企业”、“农业产业化国家重点龙头企业”等荣誉复审,作为植物提取行业绿色转型升级的示范标杆企业更是取得了“国家级绿色工厂”的荣誉称号。","serverTime":1732410086894,"listedPrice":9.89,"stockholders":"57010人(较上一季度减少4.22%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"莱茵生物(002166)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供莱茵生物(002166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"莱茵生物,002166,莱茵生物股票,莱茵生物股票老虎,莱茵生物股票老虎国际,莱茵生物行情,莱茵生物股票行情,莱茵生物股价,莱茵生物股市,莱茵生物股票价格,莱茵生物股票交易,莱茵生物股票购买,莱茵生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"莱茵生物(002166)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供莱茵生物(002166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}